OncoPharm

Topics covered: 1. Trilaciclib's approval to minimize bone marrow suppression 2. Cemiplimab's approval for mNSLC with high PD-L1 expression 3. A brief anti-BCMA CAR-T phase II trial in multiple myeloma 4. Confirmation of enfortumab vedotin's benefit in metastatic bladder cancer 5. More of the same with lenvatinib + pembrolizumab in mRCC

Happy Birthday to a drug that ushered in its own era! We discuss its history and development and just a little bit about its benefit, role, and a few clinical pearls.

Discussing the latest TKI approval, umbralisib, and its familiar toxicity profile. Also, a few final words on a new CAR-T product and a cemiplimab expanded approval.

The podcast dives into the recent FDA approval of tepotinib for metastatic non-small cell lung cancer. It provides an engaging comparison with capmatinib, highlighting differences in pharmacology and dosing. The hosts discuss side effects and ongoing research, offering insights into the efficacy of these treatments. Overall, the conversation sheds light on how these therapies fit into patient care and what this means for the future of lung cancer treatment.

With the recent FDA-approval of nivolumab + cabozantinib for metastatic renal cell carcinoma (mRCC, we review Checkmate-9ER results and how they compare to other combination treatments in mRCC. We then end by discussion preliminary recommendations on vaccinating patients with cancer agains COVID-19. Checkmate-9ER abstract: https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/nivolumab-cabozantinib-vs-sunitinib-in-first-line-treatment-for-advanced-renal-cell-carcinoma-first-results-from-the-randomized-phase-iii-checkmate-9er-trial

Discussing recent FDA approvals for expanded indications for trastuzumab-deruxtecan for gastric cancer (based on DESTINY-Gastric01) and SC daratumumab for AL amyloidosis. DESTINY-Gastric01: https://www.nejm.org/doi/full/10.1056/NEJMoa2004413

Our landmarks of OncoPharm series returns to discuss JBR10, adjuvant cisplatin/vinorelbine in NSCLC. JBR10: https://www.nejm.org/doi/pdf/10.1056/NEJMoa043623 JBR10 Update: https://pubmed.ncbi.nlm.nih.gov/19933915/ LACE meta-analysis: https://pubmed.ncbi.nlm.nih.gov/18506026/

This discussion unveils five significant FDA updates from December 2020, emphasizing pralcetinib's new role in RET-mutated medullary thyroid cancer. Delve into the clinical promise of HER2-targeting margituximab for breast cancer. Explore the safety of relugolix in hormone-sensitive prostate cancer treatments and recent advancements in selenexor and its Boston study. The intricate pharmacokinetics of new drugs also sheds light on tailored dosage strategies in oncology pharmacy.

Delve into the remarkable journey of trastuzumab, a game-changing cancer therapy stemming from the HER2 gene discovery. Discover how groundbreaking clinical trials and collaborations have paved the way for its use in breast cancer treatment, showcasing inspiring patient success stories. The discussion also highlights the drug's efficacy and safety, including potential risks like cardiomyopathy, ongoing monitoring strategies, and evolving treatment advancements for HER2-positive cases.

Highlighting some of the bright spots, oncopharm & otherwise, for our Holiday episode. Best new drug? Best study? Best movie to take my mind off of a pandemic? Enjoy this episode with a glass of Holiday Cheer.